Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites
- PMID: 2029802
- DOI: 10.2165/00003088-199120010-00004
Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites
Abstract
The disposition of phenazone (antipyrine), a low extraction compound with low protein binding, is known to be altered in the presence of various types of hepatic dysfunction. As such, its pharmacokinetics may be useful in the objective characterisation of altered liver function. Understanding the known effects of various liver disease states upon the disposition of this probe may provide insight into future applications. This article provides a review of background information about normal plasma phenazone pharmacokinetics, urinary metabolite disposition and tabulations of reported total body clearances of the drug in the presence of cirrhosis, fatty liver, hepatitis and cholestasis in humans. An estimate is made of the sensitivity and specificity of phenazone testing for the verification of the presence of cirrhosis based on this compiled literature.
Similar articles
-
Phenazone metabolism in patients with liver disease.Eur J Clin Invest. 1976 Jan 30;6(1):21-6. doi: 10.1111/j.1365-2362.1976.tb00489.x. Eur J Clin Invest. 1976. PMID: 1253807
-
Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.Clin Pharmacokinet. 1993 Apr;24(4):333-43. doi: 10.2165/00003088-199324040-00006. Clin Pharmacokinet. 1993. PMID: 8491059 Clinical Trial.
-
Pharmacokinetics of phenazone (antipyrine) in rabbits with experimental common bile duct obstruction.Br J Pharmacol. 1996 Jan;117(1):1-4. doi: 10.1111/j.1476-5381.1996.tb15146.x. Br J Pharmacol. 1996. PMID: 8825335 Free PMC article.
-
[Phenazone and its value as an indicator of metabolic efficiency of the liver].Postepy Hig Med Dosw. 1987 Mar-Apr;41(2):136-51. Postepy Hig Med Dosw. 1987. PMID: 3313327 Review. Polish. No abstract available.
-
Noninvasive assessment in vivo of hepatic drug metabolism in health and disease.Ann N Y Acad Sci. 1984;428:293-307. doi: 10.1111/j.1749-6632.1984.tb12305.x. Ann N Y Acad Sci. 1984. PMID: 6378027 Review.
Cited by
-
Assessment of liver metabolic function. Clinical implications.Clin Pharmacokinet. 1994 Sep;27(3):216-48. doi: 10.2165/00003088-199427030-00005. Clin Pharmacokinet. 1994. PMID: 7988103 Review.
-
Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.Clin Pharmacokinet. 1995 Nov;29(5):370-91. doi: 10.2165/00003088-199529050-00005. Clin Pharmacokinet. 1995. PMID: 8582120 Review.
-
Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function.Eur J Clin Pharmacol. 1995;49(3):229-35. doi: 10.1007/BF00192384. Eur J Clin Pharmacol. 1995. PMID: 8666000
-
The antioxidative activity of riboflavin in the presence of antipyrin. Spectroscopic studies.J Fluoresc. 2008 Sep;18(5):953-9. doi: 10.1007/s10895-008-0354-x. Epub 2008 Mar 20. J Fluoresc. 2008. PMID: 18351301
-
Antipyrine clearance and metabolite formation in primary biliary cirrhosis.Dig Dis Sci. 2001 Feb;46(2):352-9. doi: 10.1023/a:1005661117739. Dig Dis Sci. 2001. PMID: 11281185
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials